Catalyst Funds Management Pty Ltd
Position in PYXS — Pyxis Oncology, Inc.
CIK 1896150
SYDNEY NSW, C3
Position in PYXS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$29,784
+$4,264 QoQ
Shares Held
20,400
-12.1% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#46
of 78 holders
Holding Since
Jun 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PYXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalyst Funds Management Pty Ltd holds $21,833,824 across 56 Biotechnology names. PYXS ranks #49 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
66,261 | $6,443,882 | |
| 2 | RPRX |
Royalty Pharma plc
|
79,147 | $3,796,681 | |
| 3 | MRNA |
Moderna, Inc.
|
55,363 | $2,812,440 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
11,200 | $763,056 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
25,031 | $693,358 | |
| 6 | ABVX |
Abivax S.A.
|
5,000 | $556,750 | |
| 7 | NKTR |
Nektar Therapeutics
|
6,700 | $482,065 | |
| 8 | DMRA |
Damora Therapeutics, Inc.
|
17,293 | $447,888 |
All Filings in PYXS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,784 | 20,400 | Shares | Sole | 2026-05-11 | |
| 2025-06-30 | $25,520 | 23,200 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||